ANT2 CRISPR/Cas9 KO Plasmid (h): sc-400680
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- ANT2 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the ANT2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: ANT2 Antibody (F-7): sc-518109
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
ANT2 CRISPR/Cas9 KO Plasmid (h) | sc-400680 | 20 µg | $397.00 |
Overview
SLC25A5 encodes adenine nucleotide translocase 2 (ANT2), a mitochondrial inner membrane carrier that exchanges ADP and ATP between the matrix and cytosol, coupling oxidative phosphorylation to cellular energy demand. ANT2 contributes to mitochondrial membrane potential homeostasis and is functionally linked to pathways governing bioenergetics, redox balance, and cell survival, including permeability transition and apoptotic signaling. As a widely expressed human isoform with context-dependent regulation, ANT2 is frequently studied in proliferative states and metabolic remodeling where shifts in ATP/ADP flux influence growth and stress responses. Dysregulation of mitochondrial nucleotide transport and ANT family activity is associated with mitochondrial dysfunction phenotypes and has been investigated across cancer metabolism and neuromuscular and neurodegenerative disease research contexts.
ANT2 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the SLC25A5 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the SLC25A5 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the SLC25A5 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish ANT2 protein expression.
This CRISPR knockout system enables efficient generation of SLC25A5-deficient cell models for investigation of ANT2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting SLC25A5 exon(s) critical for ANT2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple SLC25A5 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by ANT2 CRISPR/Cas9 KO Plasmid (h) and ANT2 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the SLC25A5 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by ANT2 HDR Plasmid (h) and ANT2 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by SLC25A5 homology arms to support homology-directed repair at defined SLC25A5 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.